BTeK Consulting is a specialized consulting firm focusing in business development, licensing, and new venture efforts for life science industry. BTeK was founded by Dr. Kia Motesharei, an executive with over 20 years of experience in pharmaceutical and biotechnology industry.
DR. KIA MOTESHAREI
Dr. Motesharei has extensive transaction experience, having completed over 100 deals, including financing and M&A agreements with pharmaceutical, biotechnology, and academic institutes.
Kia Motesharei is a biopharmaceutical industry leader with experience and expertise across immunology, neurology, oncology, cardiovascular, metabolic, fertility, infectious, and rare disease indications. He is strongly networked within the pharmaceutical industry in the United States, Europe, Asia Pacific, Latin America, and the Middle East, with expertise in sell- and buy-side transactions for preclinical, clinical, and marketed therapeutic products and a proven record of success in generating value for stakeholders and investors.
Most recently, Kia was on the executive leadership team at Akcea Therapeutics, a late-stage development and commercial biopharmaceutical company focused on rare diseases. He oversaw business development and licensing activities, including search and evaluation, due diligence, transaction, and alliance management in rare disease, cardiovascular, and neurology. He led and executed the regional partnership of the company’s marketed products Tegsedi® and Waylivra® in Europe, the Middle East, and North Africa with Sobi.
Prior to joining Akcea, Kia headed Global Licensing & Business Development, Neurology & Immunology (N&I) at EMD Serono, the biopharmaceutical business of Merck KGaA. He was on the N&I Franchise Leadership Team that executed the overall strategy of the $1.8B franchise, including product and pipeline development, partnering, regulatory, and commercial and marketing decisions. He managed the global licensing team responsible for search and evaluation and transactions across the entire R&D spectrum for the immunology, neurology, allergy, fertility, medical device, and global health franchises.
Previously, Kia was a member of the management team and investor team at Dyax Corporation, a pharmaceutical company focused on development and commercialization of novel biotherapeutics for prevention of Hereditary Angioedema (HAE). He led the business development, alliance management, and competitive intelligence functions. Earlier in his career, Kia held a series of progressive leadership positions at Genfit Corporation, ActivX Biosciences Inc., and Lion Bioscience Inc.
Kia holds a PhD in Organic Chemistry from the University of California in Los Angeles, CA, and a BA in Chemistry from Colorado College, Colorado Springs, CO. He completed his postdoctoral training as an NIH Fellow at the Scripps Research Institute in La Jolla, CA.